Fig. 2
DU145 cells with the T804A substitution are resistant to periplogenin treatment, both in vitro and in vivo. (A) CRISPR/Cas9 engineered DU145 cell clones with T804A substitution (T804A) were treated with periplogenin for 72 h in the indicated dose and compared to wild type DU145 cells (WT). (B) Comparison of relative tumor volumes among all groups, the tumor volume was measured using caliper every 2 days and calculated as length x width2 × 0.5, then was normalized to tumor volume of 0 day post-administration, the relative tumor volumes of the last time point were compared. (C, D) Comparison of tumor weight and size. * and ** indicate p values of < 0.05, < 0.01, respectively, ns, not significant.
